近期升高的抗胆碱能负荷与急性心血管事件风险的关联:全国性病例-病例-时间-对照研究
该研究利用台湾全民健康保险研究数据库,纳入2011–2018年因急性心血管事件(心肌梗死、卒中、心律失常、传导障碍及心血管死亡)住院的317446例≥65岁成人;采用病例-病例-时间-对照设计,用抗胆碱能认知负荷量表评分,比较事件前30天(危险期)与随机选取的30天参考期(-61至-180天)的抗胆碱能负荷。交叉分析纳入248579例当前病例,平均年龄78.4岁(标准差0.01),53.4%为男性。1–2分 vs 0分时病例-病例-时间-对照OR为1.38(95%CI 1.34–1.42),≥3分 vs 0分OR为2.03(1.98–2.09),≥3分 vs 1–2分OR为1.48(1.44–1.52)。结论认为近期升高的抗胆碱能负荷与急性心血管事件风险升高相关,且负荷升高越多风险越高。
要点
- ≥65岁成人中,近期抗胆碱能负荷1–2分 vs 0分,急性心血管事件病例-病例-时间-对照OR 1.38(95%CI 1.34–1.42)。
- 近期负荷≥3分 vs 0分OR 2.03(95%CI 1.98–2.09);≥3分 vs 1–2分OR 1.48(95%CI 1.44–1.52),负荷越高风险越高。
- 最常处方的抗胆碱能药物为抗组胺药(68.9%)、胃肠道解痉药(40.9%)和利尿剂(33.8%)。
- 危险期(事件前1–30天)携带更高抗胆碱能负荷的患者多于参考期(-61至-180天),如1–2分危险期/0分参考期17603例 vs 0分危险期/1–2分参考期8507例。
- 敏感性分析(重新定义抗胆碱能负荷分类切点、使用不同量表)结果一致。
适用人群与场景
- ≥65岁成人,2011–2018年因新发急性心血管事件(心肌梗死、卒中、心律失常、传导障碍及心血管死亡)住院者。
诊断标准与关键阈值
- 抗胆碱能认知负荷量表评分:对各药物抗胆碱能评分求和,分为0分、1–2分、≥3分三个水平。
- 危险期:心血管事件前第1–30天(day -1至-30);参考期:随机选取的30天(第-61至-180天之间)。
研究设计与关键结果
- 研究类型:病例-病例-时间-对照研究(结合病例交叉设计与由未来病例组成的对照交叉设计),数据来自台湾全民健康保险研究数据库。
- 研究对象:317446例≥65岁因急性心血管事件住院成人;交叉分析纳入248579例当前病例,指数日平均年龄78.4岁(标准差0.01),53.4%为男性。
- 最常处方的抗胆碱能药物:抗组胺药68.9%、胃肠道解痉药40.9%、利尿剂33.8%。
- 1–2分 vs 0分:病例交叉分析OR 1.86(95%CI 1.83–1.90),对照交叉分析OR 1.35(1.33–1.38),病例-病例-时间-对照OR 1.38(1.34–1.42)。
- ≥3分 vs 0分:病例-病例-时间-对照OR 2.03(95%CI 1.98–2.09)。
- ≥3分 vs 1–2分:病例-病例-时间-对照OR 1.48(95%CI 1.44–1.52)。
- 不同时期抗胆碱能负荷分布:危险期1–2分/参考期0分17603例当前病例,危险期0分/参考期1–2分8507例当前病例,危险期携带更高负荷者更多。
- 敏感性分析(重新定义抗胆碱能负荷分类切点、使用不同量表)结果一致。
证据类型、等级与局限
- 证据类型:全国性病例-病例-时间-对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为近期升高的抗胆碱能负荷与急性心血管事件风险升高相关,且负荷升高越多风险越高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the association between recently raised anticholinergic burden and risk of acute cardiovascular events in older adults.
DESIGN: Case-case-time-control study (ie, incorporating a case crossover design and a control crossover design consisting of future cases).
SETTING: Taiwan's National Health Insurance Research Database.
PARTICIPANTS: 317 446 adults aged ≥65 who were admitted to hospital because of an incident acute cardiovascular event between 2011 and 2018. Acute cardiovascular events included myocardial infarction, strokes, arrhythmias, conduction disorders, and cardiovascular death.
MAIN OUTCOME MEASURES: The anticholinergic burden was measured for each participant by adding up the anticholinergic scores for individual drugs using the Anticholinergic Cognitive Burden Scale. Scores were classified into three levels (0 points, 1-2 points, and ≥3 points). For each participant, anticholinergic burden levels during hazard periods (day -1 to -30 before the cardiovascular event) were compared with randomly selected 30 day reference periods (ie, periods between days -61 and -180). Conditional logistic regression determined odds ratios with 95% confidence intervals to evaluate the association between acute cardiovascular events and recently raised anticholinergic burden.
RESULTS: The crossover analyses included 248 579 current cases. Participants' average age on the index date was 78.4 years (standard deviation 0.01), and 53.4% were men. The most frequently prescribed drugs with anticholinergic activity were antihistamines (68.9%), gastrointestinal antispasmodics (40.9%), and diuretics (33.8%). Among patients with varying levels of anticholinergic burden in different periods, more patients carried higher levels of anticholinergic burden during hazard periods than during reference periods. For example, 17 603 current cases had 1-2 points of anticholinergic burden in the hazard period with 0 points in the reference period, while 8507 current cases had 0 points in the hazard period and 1-2 points in the reference period. In the comparison of 1-2 points versus 0 points of anticholinergic burden, the odds ratio was 1.86 (95% confidence interval 1.83 to 1.90) in the case crossover analysis and 1.35 (1.33 to 1.38) in the control crossover analysis, which yielded a case-case-time-control odds ratio of 1.38 (1.34 to 1.42). Similar results were found in the comparison of ≥3 versus 0 points (2.03, 1.98 to 2.09) and ≥3 versus 1-2 points (1.48, 1.44 to 1.52). The findings remained consistent throughout a series of sensitivity analyses (eg, cut-off points for anticholinergic burden categories were redefined and different scales were used to measure anticholinergic burden).
CONCLUSIONS: An association was found between recently raised anticholinergic burden and increased risk of acute cardiovascular events. Furthermore, a greater increase in anticholinergic burden was associated with a higher risk of acute cardiovascular events.
参考来源
- Huang WC, Yang AS, Tsai DH, et al. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023. PMID: 37758279. doi:10.1136/bmj-2023-076045
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。